Major depressive disorder (MDD) is a highly drug-treated condition that uses an array of drug classes, including, but not limited to, selective serotonin reuptake inhibitors (SSRIs), selective…
Schizophrenia is a psychiatric disease that usually requires long-term treatment. The primary goals of treatment are to reduce the frequency and severity of psychotic episodes, maintain the…
Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals…
Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies…
The schizophrenia therapy market is very crowded, with multiple oral long-acting injectable (LAI) antipsychotic agents. Indeed, to gain a foothold in the market, differentiation from already…
Pre-exposure prophylaxis (PrEP) is a key prevention strategy for ending the human immunodeficiency virus (HIV) epidemic. The FDA’s approval of Gilead’s Truvada in 2012 and Descovy in 2019…
Clarivate expects the next 10 years to be transitional for patients with hemophilia A (with and without inhibitors) owing to the entry of several novel therapeutic options into the market. With the…
The asthma therapy market consists of many well-established treatments, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s…
The treatment landscape for squamous cell carcinoma of the head and neck (SCCHN) witnessed a major change in 2019 with the approval of Merck & Co.’s Keytruda for untreated recurrent or metastatic…
Clarivate expects the next 10 years to be transitional for patients with hemophilia A (with and without inhibitors) owing to the entry of several novel therapeutic options into the market. With the…
The treatment landscape for squamous cell carcinoma of the head and neck (SCCHN) witnessed a major change in 2019 with the approval of Merck & Co.’s Keytruda for untreated recurrent or metastatic…
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors: Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis,…
Acute myeloid leukemia (AML) is the most common form of leukemia in adults and has historically been associated with poor five-year overall survival rates. In recent years, the AML treatment…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic…
Asthma is a common chronic airway disease that affects children and adults. Environmental factors and a rapidly changing lifestyle have increased the incidence and prevalence of asthma in China…